Researchers at Stanford University have identified a small molecule tryptase inhibitor for treatment of severe allergies. Mast cells are a part of the innate and adaptive immune response. Mast Cell activation results in release of granules containing tryptases.
Ion channel dysfunctions lead to a wide array of illnesses including epilepsy, cardiac arrhythmia and type II diabetes. However, the number of clinically approved drugs for restoring normal ion channel function is limited.
Stanford researchers in the laboratory of Dr. Daria Mochly-Rosen have developed novel small molecules for modulating ALDH2 (mitochondrial aldehyde dehydrogenase-2).
Stanford researchers developed a first-in-class small-molecule inhibitor of the CLC-2 ion channel for research and drug development. CLC-2 is part of the CLC family of chloride ion channels, which regulate the flux of chloride ions across cell membranes.
Disease indication - Cancer, specifically:
-highly mutated cancers, including the ~20% of cancer with BAF complex mutations
-combination therapy with ATR inhibitors
Researchers at Stanford are developing methods of using arginine vasopressin (AVP) to improve social abilities of children with autism spectrum disorder (ASD). Autism is a neurodevelopmental disorder characterized by social impairments (e.g.
Researchers at Stanford have discovered new, chemically distinct opioid receptor ligands that may be used to develop safer opioid therapeutics. Opioids are ligands that bind to the mu, delta, and/or kappa opioid receptors.
Researchers in Dr. James Chen's lab at Stanford have discovered novel Hedgehog (Hh) pathway inhibitors that may serve as anti-cancer therapeutics. The Hh pathway plays a critical role in patterning, homeostasis, and oncogenic transformation of multiple tissues.
Stanford researchers have patented a photosynthetic system using a cyanobacterium solution that can be delivered to ischemic tissues, where blood flow is insufficient. This addresses a major clinical problem for patients with heart and vascular diseases.
The standard treatment for hepatitis C virus (HCV) is poorly tolerated and ineffective in a large subset of HCV patients. Scientists at Stanford and UCSF have developed new therapeutic leads for HCV that also have potential to be broad-spectrum anti-infectives.
Stanford and Rockefeller researchers have identified and developed dynein-specific inhibitors that have significant medical applications involving mitotic spindle assembly, organelle transport, and primary cilia formation.